Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients

AIDS

Volumn 14, Issue 5, 2000, Pages 499-507

  D'Arminio Monforte, Antonella ^a,h   Lepri, Alessandro Cozzi ^b   Rezza, Giovanni ⁱ   Pezzotti, Patrizio ⁱ   Antinori, Andrea ⁱ   Phillips, Andrew N ^b   Angarano, Gioacchino ^c   Colangeli, Vincenzo ^d   De Luca, Andrea ⁱ   Ippolito, Giuseppe ⁱ   Caggese, Liliana ⁱ   Soscia, Fabrizio ⁱ   Filice, Gaetano ^e   Gritti, Francesco ^f   Narciso, Pasquale ⁱ   Tirelli, Umberto ^g   Moroni, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ NONE

Author keywords

Discontinuation; Failure; First antiretroviral regimen; Highly active antiretroviral therapy (HAART); Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; TREATMENT FAILURE;

EID: 0242529051     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003310-00005     Document Type: Article

References (27)

1. 1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
2. 2. Cameron DW, Hearth-Chiozzi, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
3. 3. Hammer SM, Kathleen ES, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
4. 4. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
5. 5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus syndrome. N Engl J Med 1998, 338:853-860.
6. 6. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997, 11:F101-F105.
7. 7. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
8. 8. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996, 276:1955-1956.
9. 9. Fatkenheuer G, Theisen A, Roskstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
10. 10. Mocroft A, Gill MJ, Davidson W, et al. Predictors of a viral response and subsequent virological treatment failiure in patients with HIV starting a protease inhibitor. AIDS 1998, 12:2161-2167.
11. 11. d'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998, 12:1631-1637.
12. 12. Youle M, Sawyer W, for the HIV Health Economics Collaboration. Reasons for discontinuation of antiretroviral treatment: a clinical survey. AIDS 1998, 12:P186.
13. 13. Van Roon EN, Verzijl JM, Juttmann JR, et al. Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants. J Acquir Immune Defic Syndr 1999; 20:290-294.
14. 14. Anon. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Ann Intern Med 1998, 128:1079-1100.
15. 15. d'Arminio Monforte A, Pezzotti P, Arici C, et al. Determinants of initiation of antiretroviral therapy (ART) in an italian cohort of HIV-positive patients naïve from antiretrovirals (I.CO.N.A. Study). AIDS 1998, 12:P99.
16. 16. Database can be found at HYPERLINK http://www.icona.org
17. 17. Anon. 1993 Revised Classification System for HIV infection and Expanded Surveillance Case Definition for AIDS among adolescents and adults. MMWR 1992, 41:19-23.
18. 18. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 277:1962-1969.
19. 19. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
20. 20. Kastrissios H, Suarez J-R, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behaviour with a multiple drug regimen in an AIDS clinical trial. AIDS 1998, 12:2295-2303.
21. 21. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in AIDS disease. J Acquir Immune Defic Syndr 1998, 18:117-125.
22. 22. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998, 12:279-284.
23. 23. Phillips AN. Role of cohort studies. Presented at 12th World AIDS Conference, Geneva, June 28-July 3 1998.
24. 24. Feinstein A. The role of observational studies in the evaluation of therapy. Stat Med 1984, 3:341-345.
25. 25. Staszveski S, Miller V, Sabin CA, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999 (in press).
26. 26. Hoover DR, Peng Y, Saah AJ, Detels RR, Day RS, Phair JP. Using multiple decrement models to estimate risk and morbidity from specific AIDS illnesses. Multicentre AIDS Cohort Study (MACS). Stat Med 1996, 15:2307-2321.
27. 27. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280: 78-86.